An experimental gene therapy known as GC301 improved motor function and cardiac outcomes for three out of four infants with infantile-onset Pompe disease (IOPD) in a small clinical trial. The treatment was also well tolerated. One year after treatment, these three participants had reached milestones such as…
GC301
Recent Posts
- Nighttime breathing issues can emerge even with early Pompe care
- When a medical trip feels like a vacation to a child with rare disease
- Newborn screening finds more presumed LOPD cases than expected
- How I’m building a full life while living with Pompe disease
- Chronic pain affects more than 80% of late-onset Pompe disease patients